T-DXd Effective in Some With HER2+ Breast Cancer
A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those...
A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those...
BARCELONA — Adding lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) led to a significant improvement in progression-free survival in patients...
Meeting Coverage > TMS — No adverse liver effects seen with elinzanetant in OASIS 3 trial by Sophie Putka, Enterprise...
Meeting Coverage > ESMO — Hazards for radiographic PFS, OS reduced by 31% with enzalutamide plus Ra-223 by Charles Bankhead,...
Credit: CC0 Public Domain Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated...
TULSA KING SEASON 1 climaxed with a full-on Western saloon shootout that left Irish biker boss Waltrip (Ritchie Coster) very...
IT'S NICE TO have a Sunday routine, isn't it? For many Americans, Sundays consist of an early wake-up, a nice...
IT'S NICE TO have a Sunday routine, isn't it? For many Americans, Sundays consist of an early wake-up, a nice...
Credit: CC0 Public Domain Transgender and gender diverse (TGD) youth are more than five times more likely to screen positive...
Credit: Unsplash/CC0 Public Domain Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life...
Credit: Unsplash/CC0 Public Domain Limited capacity is keeping Mpox testing coverage low in the DR Congo—the epicenter of the international...
BARCELONA — The combination of standard FOLFOX chemotherapy with doublet immunotherapy did not improve progression-free survival compared with chemotherapy alone in...
BARCELONA – Adding preoperative chemoradiation to standard-of-care perioperative chemotherapy did not improve overall or progression-free survival in patients with resectable...
Adjuvant durvalumab (Imfinzi) provided no significant improvement in disease-free survival compared with placebo following resection in patients with early-stage non-small...
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of...
Meeting Coverage > TMS — Meta-analysis of 23 randomized trials showed lower HOMA-IR by Sophie Putka, Enterprise & Investigative Writer,...
Quizzes > Weekly News Quiz — You passed medical training, now see if you can pass our weekly quiz by...
Meeting Coverage > ESMO — But combination may be appropriate for shrinking tumors before surgery by Mike Bassett, Staff Writer,...
Meeting Coverage > ESMO — Second-line T-DXd best option in patients with and without intracranial activity, experts says by Mike...
TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine...